Copertina

Letter: Putting Crohn's Risk Prediction to Work in Perianal Fistula—Calibration, Thresholds, and Transport

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autore principale:	Emmanuel Pio Pastore
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulizing Crohn's Disease
di: Runqi Wang, et al.
Pubblicazione: (2026)

Editorial: Development and Validation of a Multimodal Machine Learning Model for Diagnosing and Assessing Risk of Crohn's Disease in Patients With Perianal Fistula
di: Alyssa M. Parian, et al.
Pubblicazione: (2025)

Editorial: Upadacitinib in Perianal Crohn's Disease
di: Manjeet Kumar Goyal, et al.
Pubblicazione: (2026)

Editorial: Development and Validation of a Multimodal Machine Learning Model for Diagnosing and Assessing Risk of Crohn's Disease in Patients With Perianal Fistulae: Authors' Reply
di: Lichao Qiao, et al.
Pubblicazione: (2025)

Editorial: Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulising Crohn's Disease. Authors' Reply
di: Runqi Wang, et al.
Pubblicazione: (2026)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Considerations for Outcome Measurement and Clinical Interpretation
di: Dingsheng Liu, et al.
Pubblicazione: (2025)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Critical Considerations for Outcome Measurement and Clinical Interpretation. Authors' Reply
di: Jeffrey D. McCurdy, et al.
Pubblicazione: (2025)

Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply
di: Jeffrey D McCurdy, et al.
Pubblicazione: (2025)

Editorial: Examining Perianal Fistulising Crohn's Disease Through the Lens of Wound Repair
di: Tim Eglinton
Pubblicazione: (2025)

Editorial: Mesenchymal Stem Cell Therapy for Perianal Fistulising Crohn's Disease—Effective or Hype?
di: Jeffrey D McCurdy, et al.
Pubblicazione: (2024)

One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study
di: Nicolas Richard, et al.
Pubblicazione: (2026)

Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
di: Zhidong Zhou, et al.
Pubblicazione: (2025)

Letter: The Simple Endoscopic Score for Predicting Crohn's Disease Progression—Not as Simple as It Sounds
di: Ziheng Calvin Xu, et al.
Pubblicazione: (2025)

Systematic Review of Published Guidelines: Recommendations for Exams Under Anaesthesia, Seton Insertion and Timing of Seton Removal for Perianal and Rectovaginal Fistulising Crohn's Disease
di: Edgard Medawar, et al.
Pubblicazione: (2026)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
di: Tamar Schildkraut, et al.
Pubblicazione: (2024)

Letter: Crohn's Disease or Comorbidity? Reassessing Opioid Prescribing Patterns
di: Kuan‐Ju Lin, et al.
Pubblicazione: (2025)

Letter: Geographic Transportability of Shingles Risk With Advanced IBD Therapies
di: Guofu Mao, et al.
Pubblicazione: (2026)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
di: Virginia Solitano, et al.
Pubblicazione: (2024)

Correction to ‘Stromal Vascular Fraction With Platelet‐Rich Plasma Injection During Surgery is Feasible and Safe in Treatment‐Refractory Perianal Fistulising Crohn's Disease: A Pilot Study’
Pubblicazione: (2024)

Letter: Gut microbiota—An overlooked therapeutic target in the prevention of post‐operative recurrence of Crohn's disease
di: D. Bogatic, et al.
Pubblicazione: (2024)

Letter: ‘Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study’
di: Matthias Kelm, et al.
Pubblicazione: (2025)

Letter: Extreme diagnostic delay due to misdiagnosis of gastrointestinal tuberculosis later diagnosed as postoperative Crohn's disease
di: Abhirup Chatterjee, et al.
Pubblicazione: (2024)

Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
di: Antoine Meyer, et al.
Pubblicazione: (2025)

Letter: Crohn's Disease With Latent Tuberculosis Infection or Intestinal Tuberculosis: Rapid Discrimination by Targeted Next‐Generation Sequencing
di: Maryam Irshad, et al.
Pubblicazione: (2025)

Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease
di: Jiacheng Li
Pubblicazione: (2026)

Letter: Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study: Authors' Reply
di: Nathan Grellier, et al.
Pubblicazione: (2025)

Letter: From Regional Diagnostic Thresholds to Phenotype‐Guided Management in Asian Reflux Disease
di: Jiahao Liu, et al.
Pubblicazione: (2026)

Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease. Authors' Reply
di: José Luis Rueda García, et al.
Pubblicazione: (2026)

Letter: Early real‐world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease
di: Maryam Alahmad, et al.
Pubblicazione: (2024)

Letter: From Regional Diagnostic Thresholds to Phenotype‐Guided Management in Asian Reflux Disease. Authors' Reply
di: Walter W. Chan, et al.
Pubblicazione: (2026)

Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises the Importance of Appropriate Patient Selection and Centre Expertise
di: Weilun Gao, et al.
Pubblicazione: (2024)

Letter: Risks of proton pump inhibitor treatment in cirrhotic patients
di: Jiamei Wang, et al.
Pubblicazione: (2024)

Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises Importance of Appropriate Patient Selection and Centre Expertise—Authors' Reply
di: Péter Bacsur, et al.
Pubblicazione: (2024)

Letter: The Hidden Truth of IBD Risk—From Antibiotics to Environmental Factors
di: Xueneng Yang, et al.
Pubblicazione: (2025)

Letter: Unmasking the Risks—The Need for Robust Data on Baclofen in Cirrhotic Patients
di: Zainab Salman
Pubblicazione: (2026)

Letter: Identifying the Best Model for Predicting Post‐SVR HCC
di: Hidenori Toyoda
Pubblicazione: (2025)

Letter: Diet to Modify Risk of IBD—More Plants and Less Processed Food?
di: Alice S. Day, et al.
Pubblicazione: (2025)

Letter: Enhancing Risk‐Adapted Colorectal Cancer Screening for People With Diabetes—Authors' Reply
di: Teresa Seum, et al.
Pubblicazione: (2025)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR
di: Zhejin Shi, et al.
Pubblicazione: (2026)

Letter: The Risk and Outcomes of Gastrointestinal Bleeding in Patients Using Warfarin or Direct Oral Anticoagulants
di: Jiaqi Shen, et al.
Pubblicazione: (2026)